Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000212487 | SCV000112548 | likely benign | not specified | 2015-09-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000212487 | SCV000235841 | benign | not specified | 2015-04-21 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV001085478 | SCV000560808 | benign | Duchenne muscular dystrophy | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Center for Pediatric Genomic Medicine, |
RCV000514541 | SCV000609624 | likely benign | not provided | 2017-08-28 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000212487 | SCV000711683 | benign | not specified | 2017-08-10 | criteria provided, single submitter | clinical testing | p.Arg1728Cys in exon 37 of DMD: This variant is classified as benign because it has been identified in 0.9% (180/18042) of African chromosomes, including 48 hem izygotes and 1 homozygote, by the Genome Aggregation Database (gnomAD, http://gn omad.broadinstitute.org; dbSNP rs34102501). |
Ambry Genetics | RCV000621386 | SCV000735588 | benign | Cardiovascular phenotype | 2016-11-03 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
ARUP Laboratories, |
RCV000514541 | SCV000885287 | benign | not provided | 2017-11-01 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000514541 | SCV001143750 | benign | not provided | 2019-01-09 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001167365 | SCV001329855 | uncertain significance | Dilated cardiomyopathy 3B | 2017-04-28 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000212487 | SCV001360772 | benign | not specified | 2019-12-13 | criteria provided, single submitter | clinical testing | Variant summary: DMD c.5182C>T (p.Arg1728Cys) results in a non-conservative amino acid change located in the central rod domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00099 in 203656 control chromosomes, predominantly at a frequency of 0.0097 within the African or African-American subpopulation in the gnomAD database, including 1 homozygotes. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 880 fold of the estimated maximal expected allele frequency for a pathogenic variant in DMD causing Dystrophinopathies phenotype (1.1e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. To our knowledge, no experimental evidence demonstrating its impact on protein function have been reported. Seven ClinVar submitters (evaluation after 2014) cite the variant as benign (5x) and likely benign (2x). Based on the evidence outlined above, the variant was classified as benign. |
Laboratory of Diagnostic Genome Analysis, |
RCV000514541 | SCV001797546 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000212487 | SCV001972003 | benign | not specified | no assertion criteria provided | clinical testing | ||
Diagnostic Laboratory, |
RCV000514541 | SCV001978557 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Natera, |
RCV001826752 | SCV002093529 | likely benign | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2017-08-09 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004537360 | SCV004750797 | benign | DMD-related disorder | 2019-06-10 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |